A Phase 2/3 clinical study of PTX-022 for the treatment of pachyonychia congenita
Phase of Trial: Phase II/III
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Sirolimus (Primary)
- Indications Pachyonychia congenita
- Focus Therapeutic Use
- 18 Dec 2018 According to a Palvella Therapeutics media release, the study will be commenced in Q1 2019.
- 18 Dec 2018 According to a Palvella Therapeutics media release, the company has entered into a development funding and royalties agreement with Ligand Pharmaceuticals, Inc. to advance PTX-022.
- 25 Oct 2018 New trial record